Kyowa Kirin and the Rare Diseases
Kyowa Kirin is a global pharmaceutical group based in Japan, contributing to the interest of patients and their caregivers through the discovery and commercialization of innovative medicines.
More than 7,200 employees worldwide (Japan, USA, EMEA and Asia) focus their work on the research, development and commercialization of innovative treatments, mainly in the fields of oncology, nephrology and ‘immunology.
Kyowa Kirin is also committed to the rare diseases with the upcoming arrival of two treatments:
In X-linked hypophosphatemia, an inherited pathology characterized mainly by rickets, growth retardation, deformities of the lower limbs and dental involvement.
In cutaneous T-cell lymphoma, more precisely in Mycosis Fongoïde and Sézary Syndrome
Kyowa Kirin is focusing on pathologies where medical needs remain important, relying on its unique and innovative technologies, in order to discover the molecules of tomorrow.
It is in a spirit of partnership with scientific societies, physicians, patient associations and health authorities, that our teams work to provide solutions, daily, to transform the future of patients with rare diseases.